
    
      Patients will receive intratumoral or subcutaneous injection of an oncolytic virus called PSV
      (short for Personalized Virus) every other week until the occurrence of immune related RECIST
      progression, intolerable toxicity, change to another anti-cancer treatment due to lack of
      apparent benefit, or personal choice.
    
  